Toll Free: 1-888-928-9744

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals

Published: Jun 1, 2016 | Pages: 98 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for April 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons To Buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
 Table of Contents
1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 9 2 Pharmaceuticals & Healthcare, Global, Deal Summary 12 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, April 2016 12 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, April 2016 14 2.2.1 AbbVie to Acquire Stemcentrx for up to USD9.8 Billion 14 2.2.2 Allergan Enters into Licensing Agreement with Heptares Therapeutics 15 2.2.3 Gilead Sciences Acquires Nimbus Apollo from Nimbus Therapeutics 15 2.2.4 Zymeworks Enters into Licensing Agreement with GlaxoSmithKline 16 2.2.5 Argen-X to Partner with AbbVie 17 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, April 2016 18 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, April 2016 19 3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20 3.1 Pharmaceuticals & Healthcare, Global, M&A, April 2016 20 3.1.1 Top M&A Deals in April 2016 21 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, November 2015 - April 2016 22 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, April 2016 23 3.2.1 Top Equity Offering Deals in April 2016 24 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, November 2015 - April 2016 25 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, April 2016 26 3.3.1 Top PE/VC Deals in April 2016 27 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, April 2016 28 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, April 2016 29 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, November 2015-April 2016 31 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2015-April 2016 32 4 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2016 33 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, April 2016 33 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, November 2015 - April 2016 35 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), April 2016 36 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, April 2016 37 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 38 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, November 2015 - April 2016 40 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), November 2015 - April 2016 41 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 43 5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2016 45 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, April 2016 45 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 47 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), November 2015 - April 2016 49 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), November 2015 - April 2016 51 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), November 2015 - April 2016 53 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), November 2015 - April 2016 56 5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, April 2016 57 5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, April 2016 58 5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, April 2016 59 6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 60 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, April 2016 60 6.1.1 Oncology - Deals of the Month 61 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, April 2016 64 6.2.1 Central Nervous System - Deals of the Month 65 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, April 2016 67 6.3.1 Infectious Diseases - Deals of the Month 68 6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, April 2016 69 6.4.1 Cardiovascular - Deals of the Month 70 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, April 2016 72 6.5.1 Immunology - Deals of the Month 73 6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, April 2016 75 6.6.1 Gastrointestinal - Deal of the Month 76 6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, April 2016 78 6.7.1 Metabolic Disorders - Deal of the Month 79 7 Deal Summary by Geography 81 7.1 Pharmaceuticals & Healthcare, North America Deals, April 2016 81 7.1.1 North America - Deals of the Month 82 7.2 Pharmaceuticals & Healthcare, Europe, Deals, April 2016 84 7.2.1 Europe - Deals of the Month 85 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, April 2016 87 7.3.1 Asia-Pacific - Deals of the Month 88 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, April 2016 89 7.4.1 Rest of the World - Deals of the Month 90 8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 91 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, November 2015 - April 2016 91 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, November 2015 - April 2016 93 9 Further Information 95 9.1 Methodology 95 9.2 About GlobalData 96 9.3 Disclosure information 96 9.4 Disclaimer 97
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 13 Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, April 2016 14 Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), April 2016 19 Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 21 Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, April 2016 21 Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2015 - April 2016 22 Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 24 Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, April 2016 24 Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 25 Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 27 Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, April 2016 27 Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, November 2015 - April 2016 28 Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), April 2016 30 Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 31 Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, November 2015 - April 2016 32 Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 34 Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 35 Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 37 Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), April 2016 37 Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 39 Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2015 - April 2016 42 Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), November 2015 - April 2016 44 Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 46 Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 48 Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 50 Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), April 2016 52 Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2015 - April 2016 55 Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), April 2016 57 Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, April 2016 57 Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, April 2016 58 Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, April 2016 59 Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 61 Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 65 Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 68 Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 70 Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 73 Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 76 Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 79 Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 82 Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 85 Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 88 Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 90 Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 92 Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 94


List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 12 Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), April 2016 18 Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), April 2016 19 Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 20 Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2015 - April 2016 22 Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 23 Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 25 Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 26 Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, November 2015 - April 2016 28 Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), April 2016 29 Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), April 2016 30 Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 31 Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 33 Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 35 Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 36 Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 38 Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2015 - April 2016 40 Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, November 2015 - April 2016 41 Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 43 Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 45 Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 47 Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 49 Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), November 2015 - April 2016 51 Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, November 2015 - April 2016 53 Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), November 2015 - April 2016 54 Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), April 2016 56 Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 60 Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 64 Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 67 Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 69 Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 72 Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 75 Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 78 Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 81 Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 84 Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 87 Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 89 Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 91 Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), November 2015 - April 2016 93

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...
Choose License Type
Single User - US $1000
Multi User - US $2000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify